Gastric neuroendocrine tumor, well differentiated, low or intermediate grade

Summary

Gastric neuroendocrine tumor, well differentiated, low or intermediate grade (MONDO:0015062) is a cancer (an umbrella term covering 5 Mondo subtypes) and 2 clinical trials. Top therapeutic interventions include octreotide and ribociclib. A subtype of digestive system neuroendocrine tumor, grade 1/2 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric neuroendocrine tumor, well differentiated, low or intermediate grade
Mondo ID	MONDO:0015062
NCIT	C95871
UMLS	C3272399
MedGen	474032
GARD	0025056
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	yes

Also known as: gastric NET · gastric NET G1/2 · gastric neuroendocrine tumor · gastric neuroendocrine tumour · gastric well differentiated endocrine tumor · gastric well differentiated endocrine tumor/carcinoma · gastric well differentiated endocrine tumour · GNET · well-differentiated neuroendocrine tumors of the stomach · well-differentiated neuroendocrine tumours of the stomach

Disease family

This is a subtype of digestive system neuroendocrine tumor, grade 1/2. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › gastric neuroendocrine tumor, well differentiated, low or intermediate grade

Related subtypes (9): small intestine neuroendocrine tumor, well differentiated, low or intermediate grade, gastrin-producing neuroendocrine tumor, esophageal neuroendocrine tumor, L-cell glucagon-like peptide-producing neuroendocrine tumor, neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor, rectal neuroendocrine tumor, gallbladder neuroendocrine tumor, grade 1/2, pancreatic neuroendocrine tumor, intestinal neuroendocrine tumor G1

Subtypes (5): gastric gastrin-producing neuroendocrine tumor, gastric neuroendocrine tumor G1, familial gastric type 1 neuroendocrine tumor, gastric enterochromaffin cell serotonin-producing neuroendocrine tumor, gastric neuroendocrine tumor G2

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02420691	PHASE2	COMPLETED	Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
NCT03812939	Not specified	UNKNOWN	Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OCTREOTIDE	4	1
RIBOCICLIB	4	1
CHEMBL3350037	0	1